Small Molecules

19 Oct 2019 Foamix Receives FDA Approval of AMZEEQ™ Topical Minocycline Treatment for Millions of Moderate to Severe Acne Sufferers
18 Oct 2019 AbbVie Receives CHMP Positive Opinion for Upadacitinib (RINVOQ™) for the Treatment of Adults with Moderate to Severe Active Rheumatoid Arthritis
18 Oct 2019 Janssen Receives Positive CHMP Opinion for Spravato® (esketamine) Nasal Spray for Adults with Treatment-Resistant Major Depressive Disorder
18 Oct 2019 Vertex Receives European CHMP Positive Opinion for KALYDECO® (ivacaftor) to Treat Eligible Infants with Cystic Fibrosis as Early as 6 Months of Age
18 Oct 2019 Syros Announces Update on Selective CDK7 Inhibitor Portfolio
18 Oct 2019 Plexium Launches with $28 Million in Series A Financing
18 Oct 2019 Genentech Announces FDA Approval of Xofluza (Baloxavir Marboxil) for People at High Risk of Developing Influenza-Related Complications
17 Oct 2019 Amygdala Neurosciences Announces Dosing of the First Patient in the NIH Funded Phase 2 Proof-Of-Concept study of ANS-6637 for the Treatment of Alcohol Use Disorder
17 Oct 2019 Aristea Therapeutics Announces the Completion of Enrollment in RIST4721-201, a Phase 2a Proof-of-Concept Study of RIST4721 for the treatment of Palmoplantar Pustulosis (PPP)
17 Oct 2019 Kymera Therapeutics to Present Preclinical Data Demonstrating the Potency and Antitumor Activity of a Selective STAT3 Degrader at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
17 Oct 2019 Aileron Therapeutics Announces the Initiation of Patient Treatment in its First Clinical Ph1b/2 Trial of ALRN-6924 as a Myelopreservation Agent
16 Oct 2019 Hepagene Therapeutics, Inc, Announces Dosing of First Healthy Subject in a Phase I Study of HPG1860 for NASH
16 Oct 2019 ViiV Healthcare Submits Supplemental New Drug Application to US FDA for Use of Dovato in Virologically Suppressed Adults with HIV-1
16 Oct 2019 Incyte Announces that the REACH2 Pivotal Trial of Ruxolitinib (Jakafi®) Meets Primary Endpoint in Patients with Steroid-Refractory Acute Graft-Versus-Host Disease
16 Oct 2019 Boehringer Ingelheim Announces First Patient Enrolled in Phase II Trial of Novel Cystic Fibrosis Treatment (BALANCE-CFTM 1)
16 Oct 2019 Imbrium Therapeutics Announces First Patient Dosed in Phase 2 Study of Potential First-in-Class Molecule for Insomnia Associated with Alcohol Cessation
16 Oct 2019 Denovo Biopharma Receives FDA's Permission to Proceed with a Biomarker-Guided Phase 2b Clinical Trial with DB102 (Enzastaurin) In First-Line Treatment of Glioblastoma (GBM)
15 Oct 2019 Relmada Therapeutics Announces Top-Line Results from REL-1017 Phase 2 Study in Individuals with Treatment Resistant Depression
15 Oct 2019 U.S. FDA Approves SECUADO® (asenapine) Transdermal System, the First-and-Only Transdermal Patch for the Treatment of Adults with Schizophrenia
15 Oct 2019 Principia Announces Positive Preliminary Data of PRN1008 for Immune Thrombocytopenia in Ongoing Phase 1/2 Trial
15 Oct 2019 Cyteir Therapeutics Secures Additional $40.2 Million in Its Series B Financing and Doses First Patient in Phase 1/2 Study of First-in-Class RAD51 Inhibitor
15 Oct 2019 Reata Announces Positive Topline Results from the MOXIe Registrational Trial of Omaveloxolone in Patients with Friedreich’s Ataxia
15 Oct 2019 Enterprise Therapeutics Awarded up to £5.7M ($7M) from Cystic Fibrosis Foundation to Support Clinical Development of Novel Chloride Channel Modulator
14 Oct 2019 Matinas BioPharma Initiates EnACT Study of MAT2203 (Oral Amphotericin B) for the Treatment of Fungal Cryptococcal Meningitis
14 Oct 2019 Ultragenyx Announces FDA Accepts New Drug Application for UX007 (triheptanoin) for Treatment of Long-chain Fatty Acid Oxidation Disorders

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2018 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up